ALK and non-small cell lung carcinoma: In a retrospective study using the IMMUNOTARGET registry which included 551 patients receiving ICI monotherapy for advanced NSCLC with at least one oncogenic driver alteration, 23 patients with ALK fusion NSCLC were identified (31).